Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CARG-201
- Development stage
- Preclinical
- Lead developer
- CaroGen
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CARG-201 is a first-in-class nanoparticle-based prophylactic vaccine developed by CaroGen Corporation, in collaboration with Yale University School of Medicine, for the treatment of chronic hepatitis B virus (HBV) infection. It is designed to generate multiple HBV antigens and stimulate broad immune responses by boosting both T cell and antibody-mediated immunity against HBV. The drug works through the co-expression of two HBV antigens, aiming to induce potent HBV-specific immune responses that could potentially eradicate viral antigens without requiring lifelong antiviral therapy. The underlying technology platform, AVIDIO (artificial virus for infectious diseases and immuno-oncology), was discovered at Yale University and exclusively licensed to CaroGen[1][2][4][5][6].
- Other names
- Hepatitis B vaccine CaroGen Corporation
Beyond the preview
Go deeper on CARG-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CARG-201.